Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42287 | 34979132 | J Hepatol | Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous? | 2021 | Details |
| A42288 | 34966660 | J Clin Transl Hepatol | Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. | 2021 | Details |
| A42289 | 34964947 | J Microbiol | The human symbiont Bacteroides thetaiotaomicron promotes diet-induced obesity by regulating host lipid metabolism. | 2021 | Details |
| A42290 | 34958182 | Hepatol Commun | The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. | 2021 | Details |
| A42291 | 34957482 | Diabetes | Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication. | 2021 | Details |
| A42292 | 34955407 | Int Immunopharmacol | Corrigendum to "Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3" [Int. Immunopharmacol. 100 (2021) 108126]. | 2021 | Details |
| A42293 | 34944764 | Biomedicines | The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. | 2021 | Details |
| A42294 | 34943578 | Diagnostics (Basel) | The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. | 2021 | Details |
| A42295 | 34943405 | Diagnostics (Basel) | Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population. | 2021 | Details |
| A42296 | 34935283 | Liver Int | A genetic hypothesis for burnt-out steatohepatitis. | 2021 | Details |
| A42297 | 34935193 | Fundam Clin Pharmacol | Hepatoprotective and therapeutic effects of resveratrol: A focus on anti-inflammatory and antioxidative activities. | 2022 | Details |
| A42298 | 34933916 | Gut | Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. | 2021 | Details |
| A42299 | 34931915 | Expert Rev Cardiovasc Ther | Serum uric acid: a mediator of cardio-reno-metabolic diseases. | 2021 | Details |
| A42300 | 34929350 | Ann Hepatol | Management of COVID-19 patients with chronic liver diseases and liver transplants. | 2021 | Details |
| A42301 | 34927014 | ACS Pharmacol Transl Sci | G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes. | 2021 | Details |
| A42302 | 34920141 | Clin Res Hepatol Gastroenterol | Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis. | 2021 | Details |
| A42303 | 34920140 | Clin Res Hepatol Gastroenterol | NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis. | 2021 | Details |
| A42304 | 34918436 | Diabetes Obes Metab | Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial. | 2021 | Details |
| A42305 | 34917919 | Metabol Open | DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH. | 2021 | Details |
| A42306 | 34915503 | J Innate Immun | Immunometabolism: Where Immunology and Metabolism Meet. | 2021 | Details |
| A42307 | 34915035 | Gastrointest Endosc | EUS imaging for the diagnosis of nonalcoholic fatty liver disease. | 2021 | Details |
| A42308 | 34912328 | Front Immunol | Fecal Microbiota Transplantation Controls Progression of Experimental Autoimmune Hepatitis in Mice by Modulating the TFR/TFH Immune Imbalance and Intestinal Microbiota Composition. | 2021 | Details |
| A42309 | 34911389 | J Investig Med High Impact Case Rep | Overlap of Psoriatic Arthritis and Dermatomyositis. | 2021 | Details |
| A42310 | 34907574 | Aliment Pharmacol Ther | Editorial: targeting liver biopsy in NAFLD - the need to expand non-invasive tools. | 2022 | Details |
| A42311 | 34907573 | Aliment Pharmacol Ther | Editorial: twenty minutes of moderate-to-vigorous physical activity a day keeps the NAFLD away-authors' reply. | 2022 | Details |
| A42312 | 34907567 | Aliment Pharmacol Ther | Editorial: twenty minutes of moderate-to-vigorous physical activity a day keeps the NAFLD away. | 2022 | Details |
| A42313 | 34907556 | Aliment Pharmacol Ther | Editorial: targeting liver biopsy in NAFLD-the need to expand our non-invasive tools. Authors' reply. | 2022 | Details |
| A42314 | 34897733 | JPEN J Parenter Enteral Nutr | Case presentation and panel discussion: Cardiometabolic risk mitigation. | 2021 | Details |
| A42315 | 34895506 | Lancet Gastroenterol Hepatol | The Liver Meeting Digital Experience 2021. | 2022 | Details |
| A42316 | 34894107 | Hepatol Commun | MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells. | 2021 | Details |
| A42317 | 34887111 | Clin Investig Arterioscler | Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. | 2021 | Details |
| A42318 | 34886776 | Curr Vasc Pharmacol | Cilofexor for the Treatment of Nonalcoholic Steatohepatitis | 2022 | Details |
| A42319 | 34878284 | J Agric Food Chem | Correction to Hepatic Lipidomics Analysis Reveals the Ameliorative Effects of Highland Barley β-Glucan on Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice. | 2021 | Details |
| A42320 | 34876963 | Oxid Med Cell Longev | Early-Life Exposure to Low-Dose Cadmium Accelerates Diethylnitrosamine and Diet-Induced Liver Cancer. | 2021 | Details |
| A42321 | 34875311 | J Hepatol | Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. | 2021 | Details |
| A42322 | 34871785 | Ann Hepatol | Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease. | 2021 | Details |
| A42323 | 34870213 | Radiol Artif Intell | Deep Learning Prediction of Voxel-Level Liver Stiffness in Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A42324 | 34869497 | Front Med (Lausanne) | Editorial: New Insights Into Understanding and Managing NAFLD. | 2021 | Details |
| A42325 | 34863028 | Liver Int | NAFLD vs ALD: The unresolved duel between the bad and the worst. | 2021 | Details |
| A42326 | 34863020 | Liver Int | NAFLD vs ALD: What if there was only one entity? | 2022 | Details |
| A42327 | 34855340 | FP Essent | Liver Disease: Cirrhosis. | 2021 | Details |
| A42328 | 34853788 | Biomed Res Int | The Association between Anthropometry Indices and Serum Concentrations of Gamma-Glutamyl Transferase, Alkaline Phosphatase, Alanine Aminotransferase, and Aspartate Aminotransferase. | 2021 | Details |
| A42329 | 34852424 | Ultrasonography | Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques. | 2021 | Details |
| A42330 | 34850389 | FEBS Lett | Immune cell profile and immune-related gene expression of obese peripheral blood and liver tissue. | 2021 | Details |
| A42331 | 34848185 | Cell Mol Gastroenterol Hepatol | HIF2α Activation in NASH: A New Force Pushing Toward HCC. | 2021 | Details |
| A42332 | 34847647 | Diabetes Metab J | Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). | 2021 | Details |
| A42333 | 34847645 | Diabetes Metab J | Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). | 2021 | Details |
| A42334 | 34847626 | Clin Mol Hepatol | Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time? | 2021 | Details |
| A42335 | 34840727 | Clin Liver Dis (Hoboken) | Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Nonalcoholic Fatty Liver Disease Fibrosis Than Men: Summary of the Findings of a Systematic Review and Meta-analysis. | 2021 | Details |
| A42336 | 34832073 | Membranes (Basel) | Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases. | 2021 | Details |
| A42337 | 34825869 | Curr Drug Metab | Regulatory Effects of N-3 PUFAs on Pancreatic β-cells and Insulin-sensitive Tissues. | 2021 | Details |
| A42338 | 34822801 | Gastroenterology | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42339 | 34822790 | Cell Mol Gastroenterol Hepatol | Ste20-like Kinase STK25: A Potential Target in Prevention and Therapy of NASH-Associated Hepatocellular Carcinoma? | 2021 | Details |
| A42340 | 34816691 | Arch Iran Med | Fatty Liver in COVID-19: A Risk Factor or a Common Receptor? | 2021 | Details |
| A42341 | 34816326 | J Gen Intern Med | Nonalcoholic Fatty Liver Disease Underdiagnosis in Primary Care: What Are We Missing? | 2021 | Details |
| A42342 | 34813941 | Clin Gastroenterol Hepatol | Symptom Classes in Decompensated Liver Disease. | 2021 | Details |
| A42343 | 34813919 | J Hepatol | Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease. | 2021 | Details |
| A42344 | 34809444 | Circ Res | Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome. | 2021 | Details |
| A42345 | 34808296 | Am J Kidney Dis | Recovery From Dialysis-Treated Acute Kidney Injury in Patients With Cirrhosis: A Population-Based Study. | 2021 | Details |
| A42346 | 34806817 | Liver Transpl | Utilizing Macrosteatotic Allografts for Nonalcoholic Steatohepatitis Recipients. | 2021 | Details |
| A42347 | 34805236 | Front Med (Lausanne) | Editorial: Organ Fibrosis: Pathogenesis, Biomarkers and Therapeutic Targets. | 2021 | Details |
| A42348 | 34802215 | Clin Mol Hepatol | Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment. | 2021 | Details |
| A42349 | 34801249 | J Hepatol | Liquid biomarkers for fibrotic NASH - progress in a complex field. | 2021 | Details |
| A42350 | 34800903 | EBioMedicine | Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics. | 2021 | Details |
| A42351 | 34788881 | Drug Res (Stuttg) | 2021 | Details | |
| A42352 | 34787854 | Eur Rev Med Pharmacol Sci | Diagnostic protocols in oncology: workup and treatment planning. Part 2: Abbreviated MR protocol. | 2021 | Details |
| A42353 | 34779503 | Mol Med Rep | Efferocytosis in multisystem diseases (Review). | 2021 | Details |
| A42354 | 34778594 | J Clin Transl Res | Tagging incidental finding of fatty liver on ultrasound: A novel intervention to improve early detection of liver fibrosis. | 2021 | Details |
| A42355 | 34774637 | J Hepatol | Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". | 2021 | Details |
| A42356 | 34774458 | Rev Gastroenterol Mex (Engl Ed) | Evaluation of fibrosis in patients with nonalcoholic fatty liver disease. | 2021 | Details |
| A42357 | 34774158 | Lancet Gastroenterol Hepatol | Metabolic-associated fatty liver disease in children and adolescents: Mexican experience. | 2021 | Details |
| A42358 | 34772595 | Nutrition | Authors' response re. "May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases?" | 2021 | Details |
| A42359 | 34767670 | Biofactors | Vitamin D3 enhances the effects of omega-3 oils against metabolic dysfunction-associated fatty liver disease in rat. | 2021 | Details |
| A42360 | 34766515 | Physiol Genomics | Systems genetics analysis defines importance of TMEM43/LUMA for cardiac- and metabolic-related pathways. | 2021 | Details |
| A42361 | 34766492 | Probl Endokrinol (Mosk) | [Hepatopulmonary syndrome: a rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma]. | 2021 | Details |
| A42362 | 34764874 | Front Pharmacol | Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy? | 2021 | Details |
| A42363 | 34762134 | JAMA | Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42364 | 34760761 | J Family Med Prim Care | Nonalcoholic fatty liver disease in lean and obese patients in Saudi patients from a single center. | 2021 | Details |
| A42365 | 34757151 | Clin Res Hepatol Gastroenterol | Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease? | 2021 | Details |
| A42366 | 34755226 | J Med Ultrason (2001) | Development of US- and CT/MRI-based quantification of liver steatosis. | 2021 | Details |
| A42367 | 34753791 | J Clin Pathol | Improved pathology reporting in NAFLD/NASH for clinical trials. | 2021 | Details |
| A42368 | 34750514 | Int J Obes (Lond) | Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. | 2021 | Details |
| A42369 | 34748894 | J Hepatol | Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver". | 2021 | Details |
| A42370 | 34741331 | Aliment Pharmacol Ther | Letter: cross-linkage between bacterial taxonomy and gene functions-a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. | 2021 | Details |
| A42371 | 34741327 | Aliment Pharmacol Ther | Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors' reply. | 2021 | Details |
| A42372 | 34741326 | Aliment Pharmacol Ther | Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity. | 2021 | Details |
| A42373 | 34741325 | Aliment Pharmacol Ther | Editorial: statin use in patients with NAFLD-safety concerns, decreased awareness or both? | 2021 | Details |
| A42374 | 34741324 | Aliment Pharmacol Ther | Editorial: biomarkers for alcohol-related liver fibrosis-almost there? Authors' reply. | 2021 | Details |
| A42375 | 34740615 | Cell Mol Gastroenterol Hepatol | The Role of Natural Killer Cells in Nonalcoholic Steatohepatitis: An Ongoing Debate. | 2021 | Details |
| A42376 | 34739624 | Dig Dis Sci | Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography. | 2021 | Details |
| A42377 | 34738233 | J Clin Pharmacol | Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment. | 2022 | Details |
| A42378 | 34733946 | Ann Transl Med | Wilson disease and the differential diagnosis of its hepatic manifestations: a narrative review of clinical, laboratory, and liver histological features. | 2021 | Details |
| A42379 | 34730107 | Gut Liver | Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. | 2021 | Details |
| A42380 | 34729135 | Int J Prev Med | The Importance of Visceral Adipose Tissue Detected by Imaging Methods to Assess Nonalcoholic Fatty Liver Disease Properly. | 2021 | Details |
| A42381 | 34725496 | Nat Rev Gastroenterol Hepatol | Lanifibranor and NASH resolution. | 2021 | Details |
| A42382 | 34724297 | Hepatol Res | Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. | 2021 | Details |
| A42383 | 34724294 | Hepatol Res | Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease? | 2021 | Details |
| A42384 | 34708367 | MMW Fortschr Med | 2021 | Details | |
| A42385 | 34707259 | Nat Rev Gastroenterol Hepatol | Paving the way: the road to be taken for proper NAFLD health care. | 2022 | Details |
| A42386 | 34704503 | Crit Rev Food Sci Nutr | Effects and mechanisms of tea on obesity. | 2021 | Details |